文章核心观点 - Banzai International, Inc.已收到纳斯达克通知重新符合最低公众持股市场价值要求[1][2] 相关目录总结 公司合规情况 - 2024年11月7日公司收到纳斯达克信件称自转移到资本市场层级后在2024年10月24日至11月6日连续10个交易日公司的最低公众持股市场价值达到100万美元或更多从而重新符合上市规则5550(a)(5)且此事已结束[2] 公司概况 - Banzai是一家为各种规模企业提供重要营销和销售解决方案的营销技术公司其客户包括Square Hewlett Packard Enterprise Thermo Fisher Scientific Thinkific Doodle和ActiveCampaign等数千家公司更多信息可访问www.banzai.io投资者可访问https://ir.banzai.io/ [3]

关于VYVGART Hytrulo获批情况 - 中国国家药品监督管理局（NMPA）批准VYVGART Hytrulo用于治疗成人慢性炎性脱髓鞘性多发性神经病（CIDP）这是中国首个且唯一获批用于治疗CIDP的疗法[1] - 2024年5月Zai Lab宣布中国国家药品审评中心（CDE）接受VYVGART Hytrulo用于CIDP的补充生物制品许可申请（sBLA）并给予优先审评资格2023年9月CDE授予其突破性疗法认定[3] 关于VYVGART Hytrulo相关方表态 - argenx首席执行官表示这是针对CIDP患者的精准疗法感谢合作伙伴和NMPA期待继续合作[2] - Zai Lab总裁表示获批是一个里程碑式的成果将继续与argenx探索其他适应症[2] - 唐都医院神经内科副主任医师表示现有治疗方案存在问题VYVGART Hytrulo可改善症状减轻负担[2] 关于VYVGART Hytrulo研究情况 - NMPA的批准得到ADHERE研究积极结果的支持[2] - 在中国参与者的亚组分析中与安慰剂相比使用VYVGART Hytrulo复发风险降低69%[2] - 在研究的开放标签期接受治疗的中国参与者中有78%有临床改善的证据[2] 关于VYVGART Hytrulo产品情况 - 是一种皮下注射产品由efgartigimod alfa和重组人透明质酸酶PH20组成[4] - 单皮下注射（1000mg固定剂量）30 - 90秒内完成每周给药[4] - 在美国、欧盟、日本和中国均已获批用于不同病症[4] 关于Zai Lab与argenx合作情况 - Zai Lab拥有在大中华区开发和商业化efgartigimod的独家许可协议[5] 关于中国CIDP情况 - 中国大陆估计有50000名确诊的CIDP患者[6] - 目前的治疗方案主要是皮质类固醇和静脉注射免疫球蛋白（IVIg）血浆置换（PLEX）通常用于难治性患者[6] 关于argenx公司情况 - 是一家全球性免疫学公司致力于改善严重自身免疫性疾病患者的生活[8] - 正在评估efgartigimod在多种严重自身免疫性疾病中的应用并推进早期实验性药物的研发[8] 关于Zai Lab公司情况 - 是一家创新型、基于研究的商业化生物制药公司专注于发现、开发和商业化创新产品[9]

Nvidia and Meta Platforms led the Nasdaq-100 higher over the last two years.The Nasdaq-100 tracks the performance of the 100 largest non-financial companies listed on the Nasdaq Stock Exchange. Component weighting is adjusted quarterly in March, June, and September, and the entire index is reconstituted annually in December.The Nasdaq-100 is heavily weighted toward the technology sector, a corner of the market where the rise of artificial intelligence (AI) has been particularly impactful. Indeed, Nvidia (NV ...

关于JEPQ的基本情况 - JEPQ为摩根大通纳斯达克股票溢价收入ETF，是一只积极管理型ETF，投资于纳斯达克100指数的股票，该指数由在纳斯达克交易所交易的100只最大股票组成，长期以来以科技股为主[3]。 - 过去52周内，JEPQ价格上涨15%，若考虑股息再投资的总回报为27%，按最近一次股息支付计算，目前收益率为9.5%[5]。 JEPQ的投资策略 - 其有趣之处在于管理团队的期权策略，本质上该ETF通过出售备兑看涨期权来产生收益并传递给股东，纳斯达克100指数的科技股特性常导致波动表现，与备兑看涨期权策略相结合效果较好，因为出售期权的最佳机会往往出现在动荡时期[4]。 JEPQ的收益风险 - 收益方面，过去一年每月股息支付低至约每股0.34美元，高至0.55美元，股息可变意味着收益率会改变，对于寻求稳定收益流的投资者来说不适合[7]。 - 风险方面，出售备兑看涨期权通常会限制上涨空间，JEPQ的涨幅远不及指数，虽然理论上应有助于限制下跌，但目前尚未得到证实，同时拥有波动较大的投资可能对保守投资者造成情绪上的困扰，并且该ETF历史业绩较短，还存在不可预测的股息、有限的上涨潜力和未明确的下跌风险等[9][8][10]。

ORINDA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (“MacKenzie” or the “Company”) is pleased to announce that the Company has received approval to list its common stock on the Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “MKZR”. Trading on Nasdaq is expected to commence with the open of trading on Monday, November 11th. Shareholders are not required to take any action as a result of the uplisting. Trading on Nasdaq will enhance the visibility a ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nvni Group Limited (Nasdaq: NVNI) (“Nuvini”) received a notification letter on November 1, 2024, from Nasdaq’s Listing Qualifications Department, indicating the Company’s minimum bid price per share had been below $1.00 for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the Company’s Nasdaq listing, and shares continue to trade under “NVNI”. Under Nasda ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. This extension was provided because Biomerica currently meets the oth ...

BioHarvest Sciences Announces Uplisting to the Nasdaq Global MarketCommon Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024November 07, 2024 8:30 AM EST | Source: BioHarvest Sciences Inc.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Nasdaq Stock Market LLC h ...

DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that on November 6, 2024, it received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5450(b)(2)(C) (th ...